Skip to content
Screener

ProShares UltraPro Short NASDAQ Biotechnology ZBIO Q2 2026 earnings

Reported August 12, 2026 · Before market open

Revenue$1.0MMiss by $14.0M
EPS-$1.77Miss by $0.65
Revenue estimate$15.0M
EPS estimate-$1.12

Next report

Nov 12, 2026 (in 2 months)
Revenue estimate$1.0M
EPS estimate-$1.22

FAQ

When did ProShares UltraPro Short NASDAQ Biotechnology report Q2 2026 earnings?
ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) reported Q2 2026 earnings on August 12, 2026 before market open.
What were ProShares UltraPro Short NASDAQ Biotechnology's Q2 2026 revenue and EPS?
ProShares UltraPro Short NASDAQ Biotechnology reported revenue of $1.0M and eps of $-1.77 for Q2 2026.
Did ProShares UltraPro Short NASDAQ Biotechnology beat estimates in Q2 2026?
Revenue missed the consensus estimate of $15.0M by $14.0M. EPS missed the consensus estimate of $-1.12 by $0.65.
How did ProShares UltraPro Short NASDAQ Biotechnology's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 41.6% from $-1.25.
Where can I find ProShares UltraPro Short NASDAQ Biotechnology's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-095437) and the 10-Q periodic report (0001104659-26-095448) directly on SEC EDGAR. The filing index links above go to sec.gov.